EPCT-19. A PHASE I STUDY OF RIBOCICLIB AND EVEROLIMUS FOLLOWING RADIATION THERAPY IN CHILDREN WITH NEWLY DIAGNOSED NON-BIOPSIED DIFFUSE PONTINE GLIOMAS (DIPG) AND RB+ BIOPSIED DIPG AND HIGH GRADE GLIOMAS (HGG)

Genomic aberrations in the cell cycle and mTOR pathways have been reported in diffuse pontine gliomas (DIPG) and high-grade gliomas (HGG). Dual inhibition of CDK4/6 (ribociclib) and mTOR (everolimus) has strong biologic rationale, non-overlapping single-agent toxicities, and adult clinical experienc...

Descripción completa

Detalles Bibliográficos
Autores principales: DeWire, Mariko, Leach, James, Fuller, Christine, de Blank, Peter, Hummel, Trent, Pillay-Smiley, Natasha, Salloum, Ralph, Stevenson, Charles, Drissi, Rachid, Kumar, Shiva Senthil, Baxter, Patricia, Gass, David, Goldman, Stewart, Leary, Sarah, Lane, Adam, Campagne, Olivia, Stewart, Clinton, Fouladi, Maryam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Early Phase Clinical Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715619/
http://dx.doi.org/10.1093/neuonc/noaa222.141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715619/
http://dx.doi.org/10.1093/neuonc/noaa222.141

Ejemplares similares